All In Biotech

Drug Trial Radar · NCT01321827

Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis

Last checked: Nov 19, 2026Latest source record: Mar 16, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Apr 2011

Primary completion

Mar 2013

Study completion Dec 2015

Sponsor

Sponsor type
Academic, hospital or other
First posted
Mar 24, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of itraconazole monotherapy in patients with ABPA.

Conditions

  • Allergic Bronchopulmonary Aspergillosis

Interventions

  • GlucocorticoidsDrug

    Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma

  • ItraconazoleDrug

    Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Remission rates in the two groups at six weeks and three monthsTime frame: 6 weeks, 3 months
  2. Percentage decline in IgE levels at six weeks and three monthsTime frame: 6 weeks, 3 months
  3. Complete remission rates in the two groupsTime frame: 3 months, 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Postgraduate Institute of Medical Education and Research

    Chandigarh, Uttarakhand, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.